Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

about

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

P2860

Q37660706-F482CB33-46EC-4F31-AD7E-B0D207441BF6

P2860

Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

Item

http://www.wikidata.org/entity/Q36727919

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@ast

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@en

type

Item

label

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@ast

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@en

prefLabel

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@ast

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@en

P1476

Model-Based Analysis of Unboun ...... Dosing in the Third Trimester.

@en

P2093

H M A Prince

http://www.w3.org/2001/XMLSchema#string

J B Dumond

http://www.w3.org/2001/XMLSchema#string

J Chen

http://www.w3.org/2001/XMLSchema#string

K B Patterson

http://www.w3.org/2001/XMLSchema#string

S Malone

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of lean body mass from height and weight

Lopinavir protein binding in HIV-1-infected pregnant women.

Kaletra (lopinavir/ritonavir).

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.

Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

P304

147-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12065

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27069778

http://www.w3.org/2001/XMLSchema#string

P932

4807435

http://www.w3.org/2001/XMLSchema#string

Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

about

P2860

P2860

Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932